The CRISPR-Cas system in clinical strains of Acinetobacter baumannii: an in-silico analysis.
Arturo Martínez-TrejoJuan Manuel Ruiz-RuizLuis Uriel Gonzalez-AvilaAndrés Saldaña-PadillaCecilia Hernández-CortezRaúl de Jesús Colmenero-SolísJuan Manuel Bello-LópezGraciela Castro-EscarpulliPublished in: Letters in applied microbiology (2024)
Acinetobacter baumannii is a relevant bacterium due to its high resistance profiles. It is well known that antimicrobial resistance is primarily linked to mutations and the acquisition of external genomic material, such as plasmids or phages which the CRISPR-Cas system was related. It is known that the system can influence the acquisition of foreign genetic material and play a role in various physiological pathways. In this study, we conducted an in-silico analysis using 91 fully assembled genomes of clinical strains obtained from the NCBI database. Among the analyzed genomes, the I-F1 subtype of the CRISPR-Cas system was detected showcasing variations in architecture and phylogeny. Using bioinformatic tools we determined the presence, distribution, and specific characteristics of the CRISPR-Cas system we found possible association of the system with resistance genes but no with virulence determinants. Analysis of the system's components, including spacer sequences, suggests its potential role in protecting against phage infections, highlighting its protective function.
Keyphrases
- crispr cas
- acinetobacter baumannii
- pseudomonas aeruginosa
- genome editing
- antimicrobial resistance
- multidrug resistant
- drug resistant
- escherichia coli
- cystic fibrosis
- biofilm formation
- molecular docking
- genome wide
- klebsiella pneumoniae
- copy number
- staphylococcus aureus
- dna methylation
- gene expression
- genetic diversity
- drug induced